Scopus BioPharma products

We are developing MRI-1867, our licensed rationally designed, orally available, dual-action, hybrid, small molecule that is an inverse agonist of the CB1 receptor, as well as an inhibitor of the iNOS system.

Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the activity of the STAT3 gene by way of RNA interference. CO-sTiRNA™ also stimulates TLR9 receptors to activate the body’s immune defense to recognize and kill cancer cells.